Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

bluebird bio Inc.

www.bluebirdbio.com

Latest From bluebird bio Inc.

The Gene Therapies Are Coming – And So Are New Ways To Pay For Them

Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.

Market Access Pricing Strategies

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access

How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants surveyed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.

Pricing Debate Pricing Strategies

Deal Watch: Cancer Remains Hot Target At J.P. Morgan

Bluebird licenses Inhibrx’s single-domain antibody technology for use in constructs for CAR-T therapy generation. Jazz pays $56m up front under an engineered exosome collaboration with Codiak.

Cancer Commercial

J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room

Major deal news and exciting science lent a boisterous vibe to the drug industry's big annual business meeting. But US drug pricing and macro political issues are factors industry can't ignore – even though it tried to.

Business Strategies Leadership
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Neurology, Nervous System
  • Alias(es)
  • bluebird bio LLC
  • bluebird bio LLC
  • Genetix Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • bluebird bio Inc.
  • Senior Management
  • Nick Leschly, Pres. & CEO
    Philip Gregory, CSO
    Jeffrey Walsh, Chief Financial & Strategy Officer
    David Davidson, MD, CMO
    Joanne Smith-Farrell, PhD, SVP, Corp. Dev. & Strategy
    Alison Finger, Chief Commercial Officer
  • Contact Info
  • bluebird bio Inc.
    Phone: (339) 499-9300
    60 Binney St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register